Literature DB >> 11234255

Acarbose treatment in obesity: a controlled study.

F Bayraktar1, F Hamulu, A G Ozgen, C Yilmaz, M Tüzün, T Kabalak.   

Abstract

UNLABELLED: Acarbose is an alpha-glucosidase inhibitor which reversibly inhibits oligosaccharidase and disaccharidase at the brush border of the small intestine. The aim of this study was to observe its effectiveness in the treatment of obesity.
METHODS: Two groups of 25 obese women were put on a 15 kcal/kg/day low-calorie diet for 12 weeks. One group (the study group) received 150 mg/day acarbose for the first 2 weeks and 300 mg/day acarbose for the remaining 10 weeks. The second group (controls) received no additional treatment. Body weight, BMI, skinfold thickness, serum lipids, OGTT, and insulin and C-peptide responses to OGTT were assessed before and after the study.
RESULTS: Body weight, BMI and skinfold thickness decreased significantly in both groups. Basal insulin and triglyceride levels in the study group, total and LDL cholesterol and triglyceride levels in the control group decreased significantly. No difference was found between the two groups when these decrements were compared, but the triglyceride level fell more in the control group.
CONCLUSION: Additional acarbose therapy is not more beneficial than low-calorie diet therapy alone.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 11234255     DOI: 10.1007/bf03339987

Source DB:  PubMed          Journal:  Eat Weight Disord        ISSN: 1124-4909            Impact factor:   4.652


  14 in total

Review 1.  Insulin resistance--mechanisms, syndromes, and implications.

Authors:  D E Moller; J S Flier
Journal:  N Engl J Med       Date:  1991-09-26       Impact factor: 91.245

Review 2.  Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.

Authors:  R A DeFronzo; E Ferrannini
Journal:  Diabetes Care       Date:  1991-03       Impact factor: 19.112

3.  Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study.

Authors:  N Hotta; H Kakuta; T Sano; H Matsumae; H Yamada; S Kitazawa; N Sakamoto
Journal:  Diabet Med       Date:  1993-03       Impact factor: 4.359

4.  [Clinical efficacy and tolerance to acarbose in the treatment of non-insulin-dependent diabetic patients].

Authors:  A de Leiva; F Piñón; J Tébar; F Escobar-Jiménez; H de la Calle; J L Herrera-Pombo; J Soler; L F Pallardo; E Gil; E Guardiola
Journal:  Med Clin (Barc)       Date:  1993-03-13       Impact factor: 1.725

Review 5.  Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  S P Clissold; C Edwards
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

6.  Effect of long term acarbose (Bay g 5421) therapy on metabolic control of non insulin dependent (type II) diabetes mellitus.

Authors:  M Rodier; J L Richard; L Monnier; J Mirouze
Journal:  Diabete Metab       Date:  1988 Jan-Feb

7.  Satiety in the obese Zucker rat: effects of carbohydrate type and acarbose (Bay g 5421).

Authors:  C A Maggio; J R Vasselli
Journal:  Physiol Behav       Date:  1989-09

Review 8.  The epidemiology of obesity.

Authors:  A M Hodge; P Z Zimmet
Journal:  Baillieres Clin Endocrinol Metab       Date:  1994-07

9.  alpha-Glucosidase inhibition in obesity.

Authors:  T William-Olsson
Journal:  Acta Med Scand Suppl       Date:  1985

Review 10.  Metabolic effects of acarbose in young healthy men.

Authors:  C Couet; M Ulmer; M Hamdaoui; H M Bau; G Debry
Journal:  Eur J Clin Nutr       Date:  1989-03       Impact factor: 4.016

View more
  2 in total

1.  The Effects of Acarbose on Non-Diabetic Overweight and Obese Patients: A Meta-Analysis.

Authors:  Ai-Qing Yu; Jiong Le; Wen-Tao Huang; Bin Li; Hui-Xin Liang; Qun Wang; Yu-Ting Liu; Charlotte-Aimee Young; Mei-Ying Zhang; Shu-Lan Qin
Journal:  Adv Ther       Date:  2021-01-09       Impact factor: 3.845

2.  Evaluation of effect of acarbose consumption on weight losing in non-diabetic overweight or obese patients in Kerman.

Authors:  Akram Nakhaee; Mojgan Sanjari
Journal:  J Res Med Sci       Date:  2013-05       Impact factor: 1.852

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.